FIGURE 5.

Boxviolins for estimated IC₅₀ of different drugs between two PDAC subtypes. All drugs whose IC₅₀ are significantly different between two groups are presented on Figure 5: imatinib, HG‐6‐64‐1, GW843682X, GW2580, GSK1070916, GSK429286A, GSK269962A, GNF‐2, Cpd10, EpothiloneB, embelin, doxorubicin, dasatinib, crizonib, CP724714, CP466722, GEMCITABINE, cmk, cal‐101, bx912, Bryostatin1, bortezomib, BMS‐509744, BMS345541, FTI277, bicalutamide, BI2536, bexarotene, BAY61‐3606, IPA3, as601245, AUY922, Etoposide, AZ628, AP24534, A770041, A443654, JQ1, JNK‐9 L, mesylate, thapsigargin, rapamycin, QS11, QL‐XII‐47, pyrimethamine, PHA665752, pazopanib, parthenolide, sorafenib, NSC207895, nsc87877, NG25, MS275, mitomycin c, listinib, saracatinib, lapatinib, KIN001135, KIN001102, JW7241, JQ1, Zibotentan, ZLLNLECHO, Salubrinal, XMD885, XL184, WZ3105, UNC0638, Tubastatin A, TL2015, Tl185, Ruxolitinib, TGX221, TAK715, S‐trityl‐l‐cysteine, STF‐62247, XMD14‐99, LFM‐A13, OSU‐03012. Detail information for their IC₅₀ and p value referred to Table S6